You just read:

Fostamatinib Meets Pre-Specified Primary Endpoint in Stage 1 of Autoimmune Hemolytic Anemia (AIHA) Phase 2 Study

News provided by

Rigel Pharmaceuticals, Inc.

Oct 03, 2017, 07:30 ET